Bristol Myers Squibb (BMY) ended the recent trading session at $56.29, demonstrating a -0.16% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain ...

Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

The FDA has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in ...

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea ...

Lotte Biologics has ambitious plans for its antibody-drug conjugate and contract development and manufacturing organization ...

Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices ...

Launched on 10/18/2012, the Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Value segment of ...